MATERIAL SAFETY DATA SHEET

SECTION 1 - IDENTIFICATION OF PRODUCT AND COMPANY

Pfizer Inc
Pfizer Animal Health
235 East 42nd Street
New York, NY 10017

Emergency telephone 1-866-531-8896
Hours of operation 24 Hours
Telephone 1-800-366-5288

Product name	**Rimadyl®(Carprofen) Injectable Solution**
Chemical family	Carbazole derivative
Therapeutic use	Non-steroidal, anti-inflammatory drug (NSAID)
Description	Clear very pale, straw colored liquid

SECTION 2 - COMPOSITION

Ingredient	CAS Number	Amount
Carprofen*	53716-49-7	5.0%
Lecithin*	8002-43-5	Trade secret
Glycocholic acid*	475-31-0	Trade secret
Arginine	74-79-3	Trade secret
Benzyl Alcohol*	100-51-6	1.0%
Sodium hydroxide NF*	1310-73-2	Trade secret
Hydrochloric acid*	7647-01-0	Trade secret
Water for injection, USP	7732-18-5	Trade secret

*Hazardous

Note: Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

SECTION 3 - HAZARDS IDENTIFICATION

Signal word **WARNING!**

Statements of hazard

HARMFUL IF SWALLOWED

MAY CAUSE ALLERGIC SKIN REACTION

MAY CAUSE EYE AND SKIN IRRITATION

MAY CAUSE GASTROINTESTINAL SYSTEM EFFECTS

POSSIBLE RISK OF HARM TO THE UNBORN CHILD

Eye effects: May cause irritation (based on components).

SECTION 3 - HAZARDS IDENTIFICATION ... continued

Skin effects	May cause irritation (based on components). May cause allergic skin reaction (based on components).
Inhalation effects	An Occupational Exposure Limit has been established for this substance; see Section 8.
Ingestion effects	See 'Statements of hazard' and 'Other potential health effects' in this section.
Other potential health effects	Repeat-dose studies in animals have shown a potential to cause adverse effects on the gastrointestinal system. Anecdotal reports from facilities handling RIMADYL caplets have indicated a potential for workers to develop rashes upon exposure to dusts of the material.
NOTE:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

SECTION 4 - FIRST AID MEASURES

Skin	Remove contaminated clothing and shoes. Wash skin with soap and water. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder. If irritation occurs or persists, get medical attention.
Eyes	Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.
Inhalation	Remove to fresh air. If not breathing, give artificial respiration. Get medical attention immediately.
Ingestion	Get medical attention immediately. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

SECTION 5 - FIRE FIGHTING MEASURES

Fire fighting instructions	Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Evacuate area and fight fire from a safe distance.
Extinguishing media	Use carbon dioxide, dry chemical, or water spray.
Flash point	No data available

SECTION 5 - FIRE FIGHTING MEASURES ... continued

Hazardous combustion products	May emit toxic fumes of carbon monoxide, carbon dioxide, oxides of nitrogen, hydrogen chloride and other chlorine-containing compounds

SECTION 6 - ACCIDENTAL RELEASE MEASURES

General	Review Sections 3, 8 and 12 before proceeding with clean up.
Small spill	Absorb spills with non-combustible absorbent material and transfer into a labeled container for disposal. Clean spill area thoroughly.
Large spill	Collect spill with a non-combustible absorbent material. Transfer all waste to a labeled container and move it to a secure holding area.

SECTION 7 - HANDLING AND STORAGE

General handling	Use only in a well-ventilated area. Avoid breathing vapor or mist.
Storage conditions	Store in a cool, dry, well-ventilated area.
Temperature range for storage	Store as directed by product packaging.

SECTION 8 - EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure limits

Compound	Issuer	Type	OEL
Carprofen	Pfizer	TWA-8 Hr	1 mg/m³

Measurement method	Carprofen: CAM-KAS-97-08; STP C 186.0 (contact Pfizer for additional details)
Ventilation	Engineering controls should be used as the primary means to control exposures. Local and general ventilation should be used as necessary, when handling this material in bulk. For laboratory use, handle in a lab hood.
Respiratory protection	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.
Eye protection	Safety glasses or goggles
Skin protection	Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.
Hand protection	Rubber gloves

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical form	Liquid
Color	Very pale, straw colored
Clarity	Clear
Molecular weight	Mixture
Molecular formula	Mixture
pH	7.0-7.4
Boiling point	No data available
Melting point	No data available
Density	No data available
Vapor pressure	No data available
Water solubility	No data available
Solvent solubility	No data available

SECTION 10 - STABILITY AND REACTIVITY

Reactivity	Stable under normal conditions of use.
Conditions to avoid	None known
Incompatibilities	None known
Hazardous decomposition products	None known
Hazardous polymerization	Will not occur

SECTION 11 - TOXICOLOGY INFORMATION

Toxicology summary There are no data for this formulation. The information included in this section describes the potential hazards of the active ingredient, except where noted.

Acute toxicity

Compound	Type	Route	Species	Result
Carprofen	LD_{50}	Oral	Rat	149 mg/kg
	Irritation	Dermal	Rabbit	Non-irritating
	Irritation	Ocular	Rabbit	Non-irritating
Benzyl Alcohol	Irritation	Dermal	Rabbit	Moderate
	Irritation	Ocular	Rabbit	Severe

SECTION 11 - TOXICOLOGY INFORMATION ... continued

Eye	May cause eye irritation based on components. See Acute toxicity table.
Skin	May cause skin irritation based on components. See Acute toxicity table.
Inhalation	No data available
Ingestion	See Acute toxicity table
Mutagenicity	No evidence of mutagenic or clastogenic activity in *in vitro* or *in vivo* tests.
Sensitization	Not a sensitizer in experimental animals. However, workers handling this material have developed red and blotchy patches on their hands and faces.
Subchronic effects	Subchronic oral toxicity studies for carprofen were conducted in rats and dogs for 13 weeks. In rats, daily administration of this material at dose of 5 mg/kg was well-tolerated. In dogs, daily administration of this material at dose levels of 5 and 25 mg/kg showed a slight change in serum enzyme values at the high dose (25 mg/kg); no signs of toxicity were seen at 5 mg/kg.
Chronic toxicity	Chronic oral toxicity studies for carprofen were conducted in rats and dogs. In rats, oral administration of daily doses of 1, 3, and 10 mg/kg for 2 years showed increased mortality rate, intestinal lesions, and changes in blood enzyme levels. In dogs, daily oral doses of 2 and 7 mg/kg for 1 year were well-tolerated.
Chronic effects/ carcinogenicity	No carcinogenic potential was detected in mice and rats at doses up to 10 mg/kg/day or in dogs given up to 25 mg/kg/day.
Carcinogen status	Not listed as a carcinogen by IARC, NTP or US OSHA.
Reproductive effects	Carprofen was administered to pregnant rats, mice and rabbits. No impairment of reproduction was seen in rats or mice at doses up to 20 mg/kg/day or 40 mg/kg/day respectively. In rabbits, reduced litter size and a significantly increased percentage of early and late resorptions were seen at 20 mg/kg/day. Other nonsteroidal anti-inflammatory drugs (NSAIDs) are known to impact delivery, late fetal development, and lactation. Therefore, it is recommended that exposure late in pregnancy be avoided.
Teratogenicity	No evidence of teratogenicity was observed in rats for carprofen when administered at daily oral doses of 2, 6, and 20 mg/kg. However, slightly prolonged gestation, which was associated with an increased number of dead pups at birth, was observed (this is a common finding among non-steroidal, anti-inflammatory drugs). No evidence of teratogenicity was seen in studies with mice or rabbits.
At increased risk from exposure	Individuals who have shown hypersensitivity to this material and individuals with heart conditions and impaired kidney and/or liver functions may be more susceptible to toxicity in cases of overexposure.

SECTION 12 - ECOLOGICAL INFORMATION

Environmental overview	The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

SECTION 13 - DISPOSAL INFORMATION

Disposal procedure	Incineration is the recommended method of disposal for this material. Observe all local and national regulations when disposing of this mixture.

SECTION 14 - TRANSPORTATION INFORMATION

General shipping instructions	Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

SECTION 15 - REGULATORY INFORMATION

EU Classification	Harmful; Toxic to Reproduction; Category 3
EU Labelling	**Xn**
EU Label Pictogram(s)	
Risk phrases	R22 - Harmful if swallowed. R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed. R63 - Possible risk of harm to the unborn child.
Safety phrases	S36 - Wear suitable protective clothing. S22 - Do not breathe dust. S24 - Avoid contact with skin. S53 - Avoid exposure - obtain special instructions before use.
Canadian WHMIS	Class D, Division 1, Subdivision B Class D, Division 2, Subdivision B

SECTION 16 - OTHER

Disclaimer	**Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.**